Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Lipogenesis mitigates dysregulated sarcoplasmic reticulum calcium uptake in muscular dystrophy.

Paran CW, Zou K, Ferrara PJ, Song H, Turk J, Funai K.

Biochim Biophys Acta. 2015 Dec;1851(12):1530-8. doi: 10.1016/j.bbalip.2015.09.001. Epub 2015 Sep 8.

2.

Reduced efficiency of sarcolipin-dependent respiration in myocytes from humans with severe obesity.

Paran CW, Verkerke AR, Heden TD, Park S, Zou K, Lawson HA, Song H, Turk J, Houmard JA, Funai K.

Obesity (Silver Spring). 2015 Jul;23(7):1440-9. doi: 10.1002/oby.21123. Epub 2015 May 13.

3.

Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

VanderVeen N, Paran C, Appelhans A, Krasinkiewicz J, Lemons R, Appelman H, Doherty R, Palmer D, Ng P, Lowenstein PR, Castro MG.

Mol Ther Methods Clin Dev. 2014 Feb 5;1. pii: 10.

4.

Adenoviral vector-mediated gene therapy for gliomas: coming of age.

Castro MG, Candolfi M, Wilson TJ, Calinescu A, Paran C, Kamran N, Koschmann C, Moreno-Ayala MA, Assi H, Lowenstein PR.

Expert Opin Biol Ther. 2014 Sep;14(9):1241-57. doi: 10.1517/14712598.2014.915307. Epub 2014 Apr 29. Review.

5.

Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy.

Assi HH, Paran C, VanderVeen N, Savakus J, Doherty R, Petruzzella E, Hoeschele JD, Appelman H, Raptis L, Mikkelsen T, Lowenstein PR, Castro MG.

J Pharmacol Exp Ther. 2014 Jun;349(3):458-69. doi: 10.1124/jpet.114.214619. Epub 2014 Apr 2.

6.

Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor models.

Candolfi M, Yagiz K, Wibowo M, Ahlzadeh GE, Puntel M, Ghiasi H, Kamran N, Paran C, Lowenstein PR, Castro MG.

Clin Cancer Res. 2014 Mar 15;20(6):1555-1565. doi: 10.1158/1078-0432.CCR-13-2140. Epub 2014 Feb 5.

7.

Effectiveness and preclinical safety profile of doxycycline to be used "off-label" to induce therapeutic transgene expression in a phase I clinical trial for glioma.

VanderVeen N, Paran C, Krasinkiewicz J, Zhao L, Palmer D, Hervey-Jumper S, Ng P, Lowenstein PR, Castro MG.

Hum Gene Ther Clin Dev. 2013 Sep;24(3):116-26. doi: 10.1089/humc.2013.139.

8.

Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma.

Puntel M, A K M GM, Farrokhi C, Vanderveen N, Paran C, Appelhans A, Kroeger KM, Salem A, Lacayo L, Pechnick RN, Kelson KR, Kaur S, Kennedy S, Palmer D, Ng P, Liu C, Krasinkiewicz J, Lowenstein PR, Castro MG.

Toxicol Appl Pharmacol. 2013 May 1;268(3):318-30. doi: 10.1016/j.taap.2013.02.001. Epub 2013 Feb 9.

9.

High muscle lipid content in obesity is not due to enhanced activation of key triglyceride esterification enzymes or the suppression of lipolytic proteins.

Li M, Paran C, Wolins NE, Horowitz JF.

Am J Physiol Endocrinol Metab. 2011 Apr;300(4):E699-707. doi: 10.1152/ajpendo.00316.2010. Epub 2011 Feb 1.

Supplemental Content

Support Center